Training next-generation engineers to program cells to make drugs.
Living cells serve as “factories” that churn out more than $140 billion in protein-based drugs annually. These biological factories, especially Chinese hamster ovary (CHO) cell lines, produce pharmaceuticals for people with arthritis, autoimmune diseases and much more.
Thanks to recent advances in systems biology and CHO research, including many breakthroughs made at UC San Diego, bioengineers can now control a wide range of properties of these protein-based drugs — properties that determine safety, efficacy and production cost. But there is much more work to do.
The CHO Systems Biology Center partners with industry to train the next generation of cell-line engineers to leverage emerging genomic and systems biology tools to accelerate drug development. The Center also collaborates with industry to develop new resources and techniques that empower the biopharmaceutical industry to engineer and optimize CHO cell lines for drug development.
New Era for Systems Biology
“Here at UC San Diego we are uniquely positioned to train scientists in CHO cell design and expand the CHO cell engineering toolbox. For three decades, CHO cells have been the biopharmaceutical industry workhorse. While the modus operandi for controlling drug quality included randomly screening cells, our research teams at UC San Diego are helping to open an era of rational CHO cell engineering, with the release of CHO genome sequences, systems biology models and CRISPR tools. In the hands of innovative cell engineers trained in big data analytics and systems biology, these tools will enable the design of the next generation of CHO cells.”
- — Bernhard Palsson, Ph.D.
- CHO Systems Biology Center Director
- Bernhard Palsson
- Galletti Endowed Chair Professor
- Department of
- +1 (858) 534-5668
BIG DATA ANALYTICS
FOR PRODUCT CONTROL
NEW SAFE HARBOR
CHO SYSTEMS BIOLOGY
DEEP OMICS PROFILING OF
ENGINEERED CELL LINES